18 completed, 12 active not recruiting, 4 terminated, 1 unknown. 16 Phase 2, 7 Phase 1, 6 Phase 3, 4 Not applicable, 2 Early Phase 1.
Follow Stage IIIA Breast Cancer AJCC v7: new trials by email Literature Review of Stage IIIA Breast Cancer AJCC v7 trials Research Report on Stage IIIA Breast Cancer AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration - Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Unknown | Academic and Community Cancer Research United | 480 | 2020-02-20 | 2023-12-18 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Atorvastatin, Capecitabine - Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2019-09-23 | 2024-10-02 |
| Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence Telemedicine, Best Practice, Questionnaire Administration - Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7 | Not applicable | Completed | Thomas Jefferson University | 305 | 2019-07-31 | 2026-02-05 |
| SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer Implanted Medical Device, Therapeutic Conventional Surgery - Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7 | Early Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 27 | 2019-04-07 | 2023-01-17 |
| Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors American Ginseng, Laboratory Biomarker Analysis, Placebo - Cancer Survivor, Stage I Breast Cancer AJCC v7 | Early Phase 1 | Completed | Mayo Clinic | 2 | 2019-03-01 | 2023-01-05 |
| Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration - Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 32 | 2018-10-31 | 2026-09-02 |
| Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Neratinib, Trastuzumab, Loperamide - HER2-positive Breast Cancer, Breast Adenocarcinoma | Phase 2 | Completed | University of California, San Francisco | 11 | 2018-10-09 | 2025-06-26 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Laboratory Biomarker Analysis, Pembrolizumab - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 21 | 2018-03-08 | 2026-04-03 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Radiation Therapy - Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 | Phase 3 | Completed | Mayo Clinic | 107 | 2018-02-07 | 2024-05-02 |
| Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis - Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma | Active not recruiting | Mayo Clinic | 68 | 2017-11-13 | 2026-06-09 | |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Binimetinib, Laboratory Biomarker Analysis, Pembrolizumab - Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 23 | 2017-09-27 | 2025-06-27 |
| Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors Behavioral Intervention, Questionnaire Administration - Cancer Survivor, Stage 0 Breast Cancer AJCC v6 and v7 | Not applicable | Completed | Jonsson Comprehensive Cancer Center | 133 | 2017-07-11 | 2020-07-24 |
| Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery Axillary Lymph Node Dissection, Localization, Medical Device - Breast Carcinoma Metastatic in Lymph Node, Stage II Breast Cancer AJCC v6 and v7 | Phase 4 | Completed | M.D. Anderson Cancer Center | 54 | 2017-04-11 | 2021-03-05 |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 280 | 2017-03-31 | 2026-06-30 |
| Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 805 | 2017-02-23 | 2026-07-15 |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC Carboplatin, Paclitaxel, Panitumumab - Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 43 | 2016-11-03 | 2025-11-06 |
| Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis - Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2016-09-22 | 2026-05-12 |
| Breast Cancer WEight Loss Study (BWEL Study) Health Education Program, Weight Loss Intervention - Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3177 | 2016-09-16 | 2026-09-02 |
| Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment Electroacupuncture Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 111 | 2016-09-13 | 2026-10-09 |
Showing 20 of 35. Sign in to see all of them.
Breast Neoplasms (35) · Triple Negative Breast Neoplasms (9) · Breast Carcinoma In Situ (4) · Inflammatory Breast Neoplasms (3) · Neoplasm Metastasis (3) · Breast Neoplasms, Male (2) · Carcinoma, Intraductal, Noninfiltrating (2) · Sarcoma (2) · Thyroid Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Castleman Disease (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1)
Breast Diseases (35) · Neoplasms by Site (35) · Skin Diseases (35) · Skin and Connective Tissue Diseases (35) · Neoplasms (34) · Carcinoma (7) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Carcinoma in Situ (5) · Adenocarcinoma (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Neoplastic Processes (3) · Pathologic Processes (3)
Taxes (9) · Paclitaxel (8) · Trastuzumab (8) · Ogivri (7) · PF-05280014 (7) · trastuzumab biosimilar HLX02 (7) · Ontruzant (6) · Cyclophosphamide (5) · Doxorubicin (4) · 2C4 antibody (3) · CT-P6 (3) · Carboplatin (3) · pertuzumab (3) · Aromatase Inhibitors (2) · Behavior Therapy (2)
M.D. Anderson Cancer Center (11) · National Cancer Institute (NCI) (11) · Mayo Clinic (4) · Academic and Community Cancer Research United (2) · Jonsson Comprehensive Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Rutgers, The State University of New Jersey (1) · Thomas Jefferson University (1) · University of California, San Francisco (1)
United States (35) · Canada (5) · Puerto Rico (4) · Guam (1) · Ireland (1) · Peru (1) · South Africa (1)
Clinton Yam (3) · Lorenzo Cohen (2) · Abigail S Caudle (1) · Carlos H Barcenas (1) · Carlos Vargas (1) · Ciara O'Sullivan, M.B., B.Ch. (1) · Edith A Perez (1) · Eugenia Girda, MD (1) · Filip Janku (1) · Gini F Fleming (1) · Jennifer Baker, MD (1) · Jennifer Ligibel, MD (1) · Jo Chien, MD (1) · Joseph W Kim (1) · Julienne Bower (1)
PMID 16236738, PMID 22042958, PMID 25092775, PMID 25332249, PMID 25605861, PMID 26101239, PMID 26429296, PMID 26469139, PMID 26527775, PMID 29898752, PMID 30808774, PMID 31622131, PMID 31821109, PMID 33095682, PMID 33115815, PMID 33305350, PMID 34253579, PMID 34652548, PMID 34980541, PMID 35044810, PMID 35507014, PMID 35610260, PMID 35914239, PMID 37311055, PMID 37505106, PMID 37547448, PMID 37914139, PMID 38152697, PMID 38484209, PMID 38578640, PMID 39191270, PMID 39356138, PMID 39503605, PMID 39558017, PMID 39863139, PMID 40366003, PMID 40480221, PMID 40839373, PMID 41116969, PMID 41389341, PMID 41526462, PMID 42093035, PMID 42550611
U10CA180821 (5), P30CA015083 (2), P30CA016672 (2), U10CA012027 (2), U10CA031946 (2), U10CA180868 (2), UM1CA186644 (2), UM1CA186689 (2), N01CN00035 (1), P30CA014599 (1), P30CA033572 (1), P30CA060553 (1), P30CA072720 (1), P50CA168504 (1), U01CA062505 (1)